Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Alembic Pharma receives USFDA final approval for Fulvestrant Injection

    Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single- Dose Prefilled Syringe.

  • Epigenetics breaks into the clinical practice of cancer
    Epigenetics breaks into the clinical practice of cancer

    Dr. Manel Esteller and Dr. Verónica Dávalos, researchers at the Josep Carreras Leukaemia Research Institute, describe in a new article the impact of epigenetics on cancer treatment and how it has become a crucial tool to improve early detection, predict disease progression and become a target for new treatments.

  • COVID-19 Booster Increases Durability of Antibody Response
    COVID-19 Booster Increases Durability of Antibody Response

    New research from the University of Virginia School of Medicine speaks to the benefits of a COVID-19 booster.

    The new findings shed light on how mRNA boosters – both Pfizer and Moderna – affect the durability of our antibodies to COVID-19. A booster, the researchers report, made for longer-lasting antibodies for all recipients, even those who have recovered from a COVID-19 infection.

  • Wearable Skin Patch Monitors Hemoglobin in Deep Tissues
    Wearable Skin Patch Monitors Hemoglobin in Deep Tissues

    A team of engineers at the University of California San Diego has developed an electronic patch that can monitor biomolecules in deep tissues, including hemoglobin. This gives medical professionals unprecedented access to crucial information that could help spot life-threatening conditions such as malignant tumors, organ dysfunction, cerebral or gut hemorrhages and more.

  • New DNA Analysis Provides First Accurate Tubearculosis Genome
    New DNA Analysis Provides First Accurate Tubearculosis Genome

    Researchers have developed a novel genome assembly tool that could spur the development of new treatments for tuberculosis and other bacterial infections.

    The new tool, which has created an improved genome map of one tuberculosis strain, should do likewise for other strains and other types of bacteria, according to researchers whose findings appeared in Nature Communications.

  • Genetic cause of late-onset ataxia found
    Genetic cause of late-onset ataxia found

    A new study published in the New England Journal of Medicine reports the identification of a previously unknown genetic cause of a late-onset cerebellar ataxia, a discovery that will improve diagnosis and open new treatment avenues for this progressive condition.

  • Early sign of osteoarthritis by AI will improve outcome
    Early sign of osteoarthritis by AI will improve outcome

    Researchers from the University of Jyväskylä and the Central Finland Health Care District have developed an AI based neural network to detect an early knee osteoarthritis from x-ray images. AI was able to match a doctors’ diagnosis in 87% of cases. The result is important because x-rays are the primary diagnostic method for early knee osteoarthritis. An early diagnosis can save the patient from unnecessary examinations, treatments and even knee joint replacement surgery.

  • DCGI Approves BE’s 14-Valent Pneumococcal Conjugate Vaccine
    DCGI Approves BE’s 14-Valent Pneumococcal Conjugate Vaccine

    Biological E. Limited Receives Authorization to Manufacture and Market the 14-valent Vaccine against Streptococcus pneumoniae Infection in India

  • Torrent Pharma inks with Boehringer Ingelheim to market anti-diabetics drug
    Torrent Pharma inks with Boehringer Ingelheim to market anti-diabetics drug

    Torrent Pharmaceuticals Ltd has entered into a strategic alliance with Boehringer Ingelheim India Private Limited (BI India) to co-market Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio  (Empagliflozin+ Linagliptin) in India.

  • JB Pharma to acquire Rousvastatin franchise from Glenmark Pharma
    JB Pharma to acquire Rousvastatin franchise from Glenmark Pharma

    JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, entered into an agreement with Glenmark Pharmaceuticals Ltd to acquire the Razel (Rousvastatin) franchise for the India and Nepal region. The transaction is expected to be closed within next two weeks subject to customary closing formalities.

Subscribe to Pharma News